LSL Pharma Group Announces its Results for the Third Quarter of Fiscal 2023
Revenues of $2.5M, up 25% over the last two quarters of the year;Gross margin of 18.6%, up sharply on last year's negative gross margin of (1%);Adjusted EBITDA1 of $0.1M compared with negative adjuste...